Skip to main content
Lincoln Pharmaceuticals ltd. logo

Lincoln Pharmaceuticals ltd. — Investor Relations & Filings

Ticker · LINCOLN ISIN · INE405C01035 LEI · 3358004B6OBJNW8RTT10 BSE.NS Manufacturing
Open in API
Filings indexed 453 across all filing types
Latest filing 2025-05-15 Regulatory Filings
Country IN India
Listing BSE.NS LINCOLN

About Lincoln Pharmaceuticals ltd.

https://www.lincolnpharma.com/

Lincoln Pharmaceuticals Ltd. focuses on the development, manufacturing, and marketing of a diverse range of therapeutic formulations. The organization operates advanced manufacturing facilities certified by international standards, including WHO-GMP. Its portfolio spans multiple areas such as anti-infectives, cardiovascular, gastrointestinal, respiratory, and pain management. The company is recognized for its research and development initiatives, particularly in Novel Drug Delivery Systems (NDDS). Key offerings include specialized treatments for tinnitus and a wide array of formulations in dosage forms like tablets, capsules, liquid orals, and injectables. It maintains a significant global footprint, supplying products to numerous international markets across Africa, Southeast Asia, and Latin America, supported by a robust distribution network for its extensive healthcare catalog.

Recent filings

Filing Released Lang Actions
Board Meeting — Board Meeting Intimation
Regulatory Filings
2025-05-15 English
Board Meeting — Financial Results/Dividend
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges notifying them of an upcoming Board Meeting scheduled for May 22, 2025. The purpose of the meeting includes consideration and approval of audited financial results for the quarter and year ended March 31, 2025, and recommendation of dividend. The letter also mentions the closure of the trading window as per SEBI regulations. The document does not contain the financial results themselves, nor detailed financial data, but is an announcement of the Board Meeting where such results will be approved. This fits the category of a Regulatory Filing (RNS) as it is a compliance disclosure about an upcoming event rather than the financial report or earnings release itself. The document length is short (2669 characters), and it is primarily an intimation letter, not the report or results.
2025-05-15 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a notice addressed to stock exchanges (NSE and BSE) regarding a newspaper advertisement for the transfer of equity shares to the Investor Education Protection Fund Authority (IEPF Authority). It references compliance with the Companies Act, 2013 and SEBI regulations, and includes details about unclaimed dividends and the transfer of shares if claims are not lodged. The document also contains a sale notice for immovable/movable properties under the Securitisation and Reconstruction of Financial Assets and Enforcement of Security Interest Act, 2002, indicating a public auction for recovery of debts. The content is primarily regulatory announcements and notices rather than a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis. The document is lengthy but consists mainly of notices and announcements. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2025-05-08 English
Updates
Regulatory Filings
2025-04-18 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings
2025-04-15 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings
2025-04-15 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.